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Purpose: The purpose of this study was to investigate the treatment efﬁcacy of photodynamic therapy
(PDT) with verteporﬁn for patients suffered from polypoidal choroidal vasculopathy.
Methods: In this retrospective comparative study, we included 25 eyes of 25 patients with macula-
involved polypoidal choroidal vasculopathy. All patients had follow-up of more than 3 years.
We compared the best-corrected visual acuity (BCVA) in logarithm of minimal angle of resolution
(logMAR) scale at each follow-up time points with initial baseline BCVA. We also investigated the factors
inﬂuencing ﬁnal BCVA at the 36-month follow-up time point.
Results: At 6 months, the mean BCVA improved from 0.77 to 0.68 (p ¼ 0.024). All the mean BCVAs after
the 6-month follow-up time points were still better than baseline mean BCVA, but the improvements
were not signiﬁcant statistically. The mean BCVAs became 0.68, 0.74, 0.75, 0.73, and 0.72 respectively at
12-month, 18-month, 24-month, 30-month, and 36-month follow-up time points. Better initial BCVA
(p ¼ 0.012) and smaller lesion size (p ¼ 0.031) signiﬁcantly predicted the better ﬁnal visual improvement
at 36 months rather than sex (p ¼ 0.7) and age (p ¼ 0.206).
Conclusion: Although the visual improvement after treatment of PDT with verteporﬁn was only
temporarily signiﬁcant, the prevention of visual deterioration in these patients persisted during a 3-year
follow-up. Better initial BCVA and smaller lesion size were signiﬁcant factors inﬂuencing ﬁnal visual
improvement, and early treatment might be suggested.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Polypoidal choroidal vasculopathy (PCV) was ﬁrst described by
Yannuzzi and others1 in 1990 and is characterized by peculiar
choroidal vascular networks terminating in aneurysmal or poly-
poidal lesions.2,3 These lesions often leak extensively and produce
subretinal ﬂuid (SRF), intraretinal ﬂuid (IRF), and retinal pigment
epithelium detachment (RPED).4,5 In fundus examination, the
polyps look like orange-red protruding nodules and may involve
the macular, peripapillary, midperiphery, or nasal area.2,6 The
prevalence of this disease is relative high in the Asian population,
especially the Japanese.7e9
The natural course of PCV is highly variable and depends on
factors including location, lesion sizes, and associated bleeding.almology, National Taiwan
ad, Taipei, Taiwan.
g).
e Ophthalmologic Society of TaiwOccasionally, acute and severe loss of vision may happen to PCV
patients due to massive submacular or vitreous hemorrhage from
spontaneously ruptured vessels.5,10 In a long-term natural course
study, Uyama and others5 found that 50% of patients had a favor-
able course and in the remaining 50% followed a long-term
persistent course with progressive visual loss because of recur-
rent hemorrhage or exudation. Although several treatment strate-
gies have been proposed, such as laser photocoagulation,
photodynamic therapy (PDT) with verteporﬁn, selective photo-
thrombosis, and intravitreal injection of anti-vascular endothelial
growth factor (VEGF), there is still no consensus about the most
effective treatment of PCV.11e18
PDT with verteporﬁn (Visudyne; Novartis Pharma AG, Basel,
Switzerland) has shown good results for PCV. Several studies
revealed improved or stable vision, but recurrent or newly devel-
oped lesion was not infrequent and the visual acuity would be
affected during a longer follow-up.13e15,19e21 Recently, bev-
acizumab, an anti-VEGF, has also been used to treat PCV and wasan. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics and treatment outcomes of 25 eyes of 25 patients
with polypoidal choroidal vasulopathy.
Gender
Male, no. (%) 14 (56%)
Female, no. (%) 11 (44%)
Age (years)
Mean  SD 65.2  10.1
Baseline greatest linear dimension of lesion (mm)
Mean  SD 2915  1182
Baseline log MAR BCVA
Mean  SD 0.77  0.39
RPED, no. (%) 19 (76%)
SRH, no. (%) 16 (64%)
Treatment times 3.16
Residual leakage on ICGA 1 (4%)
Residual RPED, SRF, IRF 4 (16%)
BCVA ¼ best corrected visual acuity; IRF ¼ intraretinal ﬂuid; log
MAR ¼ logarithm of minimal angle of resolution; RPED ¼ retinal pigment
epithelial detachment; SRF ¼ subretinal ﬂuid; SRH ¼ subretinal hemor-
rhage; SD ¼ standard deviation.
Fig. 1. This plot graph showing changes in mean best corrected visual acuity in log-
MAR units during the 36-month follow-up. The error bar values indicate the standard
deviation. The improvement of BCVA was only signiﬁcant statistically at 6 months
follow-up time point (* indicate p < 0.05).
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However, the choroidal lesion was unaffected by this treatment
alone.17,18,22 In this study, we reported our 3-year treatment results
of PDT with verteporﬁn for PCV patients in Taiwan.
2. Methods
This retrospective analysis was approved by the Institutional
Review Board of the National Taiwan University Hospital in Taipei,
Taiwan. Patients with macula-involved PCV and treated with PDT
with verteporﬁn from January 2007 to June 2011 were enrolled in
our study. The diagnosis of PCV was made based on the ﬁnding of
characteristic polyp-like hyperﬂuorescence with or without
a branching vascular network on indocyanine green angiography
(ICGA). The inclusion criteria were as follows: (a) juxtafoveal,
subfoveal, or extrafoveal active macular polypoidal lesions on ICGA,
(b) macula-involved active lesion, such as submacular ﬂuid, recent
hemorrhage, lipid exudates, and macular edema as evidenced by
optical coherence tomography (OCT) or ﬂuorescein angiography
(FAG), (c) initial best-corrected visual acuity worse than 20/32
[0.2 logarithm of minimum angle of resolution (logMAR)], (d)
greatest linear dimension of lesion  5400 mm, and (e) follow-up >
36 months. The exclusion criteria were as follows: (a) other ocular
disease, such as epiretinal membrane, intraocular inﬂammation or
infection, diabetic retinopathy, (b) previous treatment for PCV, (c)
any systemic contraindication to verteporﬁn or angiographic dyes,
such as porphyria, (d) severe systemic disease, such as cerebral
vascular accident, liver disease, and (e) scar tissue that accounted
for more than one-half of the PCV lesion.
Best-corrected visual acuity (BCVA), tonometry, and funduscopy
were performed before treatment and at each follow-up. OCT, FAG,
and ICGA were performed before treatment and at the 3-month
interval. Follow-up visits were arranged 1 week after treatment
and monthly thereafter. The BCVA measurement used the Snellen
chart and then was converted to logMAR values. The patients
received one session of PDT at baseline. If leaking polyps were
found on ICGA, additional sessions of PDT every 3 months would be
performed until the disappearance of the leaking polyps.
PDT with verteporﬁn infusion and laser application were per-
formed using the full-ﬂuence dose according to the Treatment of
Age-Related Macular Degeneration with Photodynamic Therapy
protocol.23 The difference in BCVA values between baseline and 6-,
12-, 18-, 24-, 30-, and 36-month follow-up time points were
analyzed using theWilcoxon signed rank test. A increase in BCVA of
more than three lines (logMAR BCVA change  3 lines) was
considered improved and a decrease of more than three lines
(logMAR scale) was considered aggravated. The percentage of BCVA
improved and aggravates were also analyzed at 6, 12, 18, 24, 30, and
36 months. Furthermore, we used linear regression test to inves-
tigate if age, sex, lesion size, and baseline BCVA had a signiﬁcant
impact on ﬁnal visual outcome at 3 years of follow-up. Paired t-test
and linear regression were performed for statistical analysis. Initial
BCVA, lesion size, sex, and age were included in linear regression
for multivariate analysis. Statistical analysis was performed using
SPSS 11.5.1 for Windows software package (SPSS Inc, Chicago, Illi-
nois, USA). A p < 0.05 was considered signiﬁcant.
3. Results
From January 2007 to June 2011, 25 eyes of 25 patients treated
for PCV with verteporﬁn in National Taiwan University Hospital
were included in our study according to the criteria described
previously. The details of patient characteristics are listed in Table 1.
The mean BCVA scores in logMAR scale over time are displayed in
Fig. 1 and Table 2. The mean BCVA at baseline was 0.77  0.39. Themean BCVAs at post-treatment at 6, 12, 18, 24, 30, and 36 months
became 0.68  0.43, 0.68  0.47, 0.74  0.47, 0.75  0.50,
0.73  0.48, and 0.72  0.48 respectively. The improvement of
BCVA was signiﬁcant statistically 6 months after treatment
(p ¼ 0.024).
As shown in Fig. 2, at the 6-month follow-up, 16% of the patients
gained vision more than three lines and 8% of the patients lost
vision more than three lines. At the 12-, 18-, and 24-month follow-
up time points, 24%, 24%, and 28% of the patients gained vision of
more than three lines, respectively; 16%, 16%, and 24% of the
patients lost vision of more than three lines, respectively. At the 30-
and 36-month follow-up time points, 24% and 24% of the patients
gained vision more than three lines, respectively; 20% and 16% of
the patients lost vision more than three lines, respectively.
During the 3 years follow-up, the patients received a mean of
3.16 treatments. At the 36-month follow-up time point, 4% patients
had residual leakage on ICGA and 16% patients had lesions with
residual RPED, SRF, or IRF (Table 1). Based on the results of
Table 2
Visual acuity during 36-month follow-up (data presented as mean  SD).
Time from initial
treatment (months)
Log MAR BCVA P value (V.S. baseline)
0 0.77  0.39
6 0.68  0.43 0.024
12 0.68  0.47 0.085
18 0.74  0.47 0.572
24 0.75  0.50 0.715
30 0.73  0.48 0.499
36 0.72  0.48 0.428
BCVA ¼ best corrected visual acuity; log MAR ¼ logarithm of minimal angle of
resolution; SD ¼ standard deviation.
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lesion size (p ¼ 0.031) signiﬁcantly predicted the better ﬁnal visual
improvement at 36 months. Sex (p ¼ 0.7) and age (p ¼ 0.206) did
not have the signiﬁcant affect on the ﬁnal BCVA change.
There was no complication such as infection, inﬂammation, or
retinal detachment happened during follow-up in all of the
patients. However, massive subretinal hemorrhage or break-
through vitreous hemorrhage developed in four eyes (16%), RPE
tear developed in three eyes (12%), and the BCVAs of these eyes all
severely deteriorated. Massive subretinal hemorrhage or break-
through vitreous hemorrhage happened in two eyes within 1 week
after PDT treatment and may associate with the treatment. The
other two eyes suffered from massive subretinal hemorrhage or
breakthrough vitreous hemorrhage 2 months after PDT treatment
and may not be associated with PDT treatment.
4. Discussion
PCV is one type of choroidal neovascularization but is different
from age-related macular degeneration (AMD). Compared with
AMD, PCV is thought to have better visual prognosis. However, once
the lesion area extending to subfoveal area, visual prognosis will be
poor.7 In order to ﬁnd out the best treatment modality, many
studies investigated and compared the effect of PDT, intravitreal
injection of anti-VEGF, or combination therapy. But, there was
much disparity existed between these studies. Romano and coau-
thors24 and Sato and others25 showed signiﬁcant visual acuityFig. 2. The rates of eyes with a BCVA improvement of 3 lines or loss 3 lines at 6, 12,
18, 24, 30 and 36 months were showed in this graph.improvement after 1 year combined treatment of PDT and intra-
vitreal injection of bevacizumab (IVB). Gomi and associates26 also
reported signiﬁcantly better results of combined therapy compared
with PDT monotherapy after 1 year of treatment. However,
according to the study of Rouvas and others,20 photodynamic
therapy resulted in a signiﬁcantly better outcome than ranibizu-
mab or PDT with ranibizumab after 1 year of follow-up. Since the
treatment results of PCV had much disparity and the case numbers
of these studies were relatively small, we reported our 3-year
results of PDT monotherapy for a better understanding of the
treatment effect.
Our results were similar to the reports of Akaza and colleauges19
andLeal and coauthors21 The visual acuity improvement was more
apparent during the ﬁrst year after treatment. However, the
improvement became less signiﬁcant with time. In our study, the
mean BCVA changed at the 3-year follow-up time point and was an
improvement of 0.07 in the logMAR scale. In the study by Akaza and
colleagues,19 a mean BCVA loss of 0.06 logMAR 3 years after PDT
treatment was reported. In the study by Leal and others,25 a mean
BCVA loss of 0.02 logMAR was reported. All of these mean BCVA
changes were not signiﬁcant statistically.
According to several previous studies, vascular lesions could be
controlled by PDT successfully, but the adverse events of RPE
damage and scar formation would occur after treatment and result
in persistent deterioration of visual acuity.27e29 Since the RPE
damage and scar formation is difﬁcult to avoid, and better initial
visual acuity results in the favorable visual outcome according to
previous andour studies, early treatment for smaller lesionwouldbe
agoodoption tominimize the tissuedamageand toobtain thebetter
prognosis.30 Furthermore, patients with subfoveal lesion usually
had the worst initial BCVA and ﬁnal BCVA compared with patients
with extrafoveal lesions. Early treatment could also prevent further
damage of retinal cells from polypoidal lesions itself.5
The limitations of this study include its small number of
patients, retrospective study design and lack of macular thickness
OCT measurement. Although the 3-year follow-up period is longer
thanmost previous studies, it is not enough to clarify the long-term
treatment outcomes and complications. On the other hand,
converting Snellen BCVA to logMAR may cause some bias in the
statistical analysis. Further studies with multicenter, double-
blindness, and long-term follow-up are necessary to conﬁrm the
best protocol for PCV treatment.
In summary, our ﬁndings demonstrated that treatment of PDT
with verteporﬁn for symptomatic PCV could temporarily improve
mean BCVA andmay prevent visual loss until three years follow-up.
Our study also illustrated that initial visual acuity and lesion size
were signiﬁcant factors that inﬂuenced ﬁnal visual improvement.
Early treatment might be suggested after diagnosis of macula-
involved PCV because patients with better initial visual acuity
and smaller lesion sizes had more prominent visual improvement
after PDT treatment.References
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